Jang G, Park R, Esteva E, Hsu P, Feng J, Upadhaya S
J Exp Med. 2025; 222(6).
PMID: 40072317
PMC: 11899982.
DOI: 10.1084/jem.20240587.
Ciantra Z, Paraskevopoulou V, Aifantis I
Nat Immunol. 2025; 26(3):351-365.
PMID: 40021898
DOI: 10.1038/s41590-025-02096-9.
Kitamura A, Yanagi S, Shide K, Sato Y, Kamiunten A, Yamanari Y
Am J Case Rep. 2024; 25:e945804.
PMID: 39736074
PMC: 11694771.
DOI: 10.12659/AJCR.945804.
Fakhar F, Mohammadian K, Keramat S, Stanek A
Nutrients. 2024; 16(23).
PMID: 39683494
PMC: 11643542.
DOI: 10.3390/nu16234100.
Liu Y, Deng Y, Yang C, Naranmandura H
Bioengineering (Basel). 2024; 11(11).
PMID: 39593745
PMC: 11591775.
DOI: 10.3390/bioengineering11111084.
The IL-1β inhibitor canakinumab in previously treated lower-risk myelodysplastic syndromes: a phase 2 clinical trial.
Rodriguez-Sevilla J, Adema V, Chien K, Loghavi S, Ma F, Yang H
Nat Commun. 2024; 15(1):9840.
PMID: 39537648
PMC: 11561093.
DOI: 10.1038/s41467-024-54290-2.
The MicroRNA miR-223 Constrains Colitis-associated Tumorigenesis by Limiting Myeloid Cell Infiltration and Chemokine Expression.
Flynn C, Markey G, Neudecker V, Farrelly C, Furuta G, Eltzschig H
J Immunol. 2024; 213(12):1869-1883.
PMID: 39485006
PMC: 11611642.
DOI: 10.4049/jimmunol.2400129.
Pathogenesis and inflammaging in myelodysplastic syndrome.
Villaume M, Savona M
Haematologica. 2024; 110(2):283-299.
PMID: 39445405
PMC: 11788632.
DOI: 10.3324/haematol.2023.284944.
Immune-dysregulation harnessing in myeloid neoplasms.
Sharifi M, Xu L, Nasiri N, Ashja-Arvan M, Soleimanzadeh H, Ganjalikhani-Hakemi M
Cancer Med. 2024; 13(17):e70152.
PMID: 39254117
PMC: 11386321.
DOI: 10.1002/cam4.70152.
Trained and ready - the case for an inflammatory memory for hematopoietic stem and progenitor cells in the AML niche.
Chen D, Wafula E, Kurre P
Oncotarget. 2024; 15:609-613.
PMID: 39236060
PMC: 11376595.
DOI: 10.18632/oncotarget.28642.
Potential Diagnostic Value of Abnormal Pyroptosis Genes Expression in Myelodysplastic Syndromes (MDS): A Primary Observational Cohort Study.
Soltani M, Sharifi M, Khalilian P, Sharifi M, Nematollahi P, Shapourian H
Int J Hematol Oncol Stem Cell Res. 2024; 18(2):156-164.
PMID: 38868810
PMC: 11166493.
DOI: 10.18502/ijhoscr.v18i2.15371.
Dysregulated innate immune signaling cooperates with RUNX1 mutations to transform an MDS-like disease to AML.
Barreyro L, Sampson A, Hueneman K, Choi K, Christie S, Ramesh V
iScience. 2024; 27(6):109809.
PMID: 38784013
PMC: 11112336.
DOI: 10.1016/j.isci.2024.109809.
Influence of donor-recipient sex on engraftment of normal and leukemia stem cells in xenotransplantation.
Mian S, Ariza-McNaughton L, Anjos-Afonso F, Guring R, Jackson S, Kizilors A
Hemasphere. 2024; 8(5):e80.
PMID: 38774656
PMC: 11107397.
DOI: 10.1002/hem3.80.
Bone marrow inflammation in haematological malignancies.
de Jong M, Chen L, Raaijmakers M, Cupedo T
Nat Rev Immunol. 2024; 24(8):543-558.
PMID: 38491073
DOI: 10.1038/s41577-024-01003-x.
In vivo ablation of NF-κB cascade effectors alleviates disease burden in myeloproliferative neoplasms.
Laranjeira A, Kong T, Snyder S, Fulbright M, Fisher D, Starczynowski D
Blood. 2024; 143(23):2414-2424.
PMID: 38457657
PMC: 11175964.
DOI: 10.1182/blood.2023022804.
Subclassification of B-acute lymphoblastic leukemia according to age, immunophenotype and microenvironment, predicts MRD risk in Mexican children from vulnerable regions.
Romo-Rodriguez R, Zamora-Herrera G, Lopez-Blanco J, Lopez-Garcia L, Rosas-Cruz A, Alfaro-Hernandez L
Front Oncol. 2024; 13:1304662.
PMID: 38250553
PMC: 10796993.
DOI: 10.3389/fonc.2023.1304662.